Zimbabwe has turned down a substantial American healthcare agreement valued at $367m (272 million pounds) over five years due to the United States' demand for confidential information.
The decision came to light after a official document from December was disclosed, revealing that President Emmerson Mnangagwa deemed the agreement was "skewed".
A government representative later clarified that the US was demanding access to genetic material for research and profit while was unwilling to guarantee the benefits from any future treatments.
"We must now begin the challenging and unfortunate process of scaling back our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for further talks to reach a deal suitable to both sides so the nation's vital HIV treatment initiative can continue.
Wider Context
This rejection comes after a similar case in Kenya, where a court halted a related health funding agreement following legal challenges were filed about the security of citizens' medical information.
After returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump claimed its expenditure was "inefficient" and his administration was pursuing government-to-government deals to enhance transparency and responsibility.
Based on statements, Sixteen African countries have to date signed similar agreements, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration would have delivered extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on antiretroviral therapy via US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its biological resources and data indefinitely, with no equivalent promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that shared data," his statement read.
"Put simply, our nation would supply the raw materials for medical research with no certainty that the end products would be accessible to our people should a new pandemic emerge."
Sovereignty and Global Health
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were disrupting systems previously set up via the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework created to deal with future pandemics.
"This system is intended to guarantee that when a nation contributes its information, the benefits – including medicines and cures – are distributed fairly, not monopolised solely by those with the capability to create them."
These objections regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We are open to ongoing dialogue with our US partners on how future co-operation could be structured in a manner that respects the independence and dignity of both nations."
Medical Community Reaction
Medical experts expressed it acknowledged the official position, but suggested that negotiations should continue given that a large portion of the nation's HIV programmes were funded by international support.
"If technical issues exist, including those involving data governance or implementation frameworks, these can often be resolved via technical clarification and negotiated safeguards," it added.
The halted deal underscores the continuing tensions between accepting vital international aid and protecting a country's data in an ever more data-driven world.